Wednesday, July 8, 2026

pharma · Metastatic Lung Non-Small Cell Carcinoma · COVID-19 · OTLC

Oncotelic Therapeutics

Oncotelic Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Seoul, KR HQ
2020 Founded
14 Employees
Public company Type
OTLC · NYSE Ticker
Company details
Status
Public
HQ
Seoul, KR
Founded
2020
Employees
14
Programs
4
Drugs
3
Patents
1
Intelligence · Clinical Programs

Oncotelic Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Oncotelic Therapeutics.

Oncotelic Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. OT-101

    Oncotelic Therapeutics

    Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial
  2. Atezolizumab

    Oncotelic Therapeutics

    Metastatic Lung Non-Small Cell Carcinoma

    phase 2 mab terminated

    1 trial
  3. OT-101

    Oncotelic Therapeutics

    COVID-19

    phase 2 small molecule active

    1 trial
  4. OT-101

    Oncotelic Therapeutics

    Malignant Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Oncotelic Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.